NEXGEL to Present at the Aegis Capital Virtual Conference on May 9, 2024
May 06, 2024 16:05 ET
|
NEXGEL, INC.
LANGHORNE, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle,...
NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday
March 27, 2024 09:00 ET
|
NEXGEL, INC.
LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...
NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th
March 21, 2024 09:00 ET
|
NEXGEL, INC.
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading...
NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th
March 04, 2024 08:30 ET
|
NEXGEL, INC.
LANGHORNE, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...
NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders
February 21, 2024 16:05 ET
|
NEXGEL, INC.
LANGHORNE, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle,...
NEXGEL Reports First Quarter 2023 Financial Results
May 15, 2023 16:05 ET
|
NEXGEL, INC.
2023 first quarter revenue increased 56.6% year-over-year to $620 thousand Approximately $5.8 million in cash and securities at March 31, 2023 Provides second quarter 2023 revenue guidance...